ClinicalTrials.Veeva

Menu

Developing an HIV Disclosure Intervention for Men in Uganda (DASH)

Mass General Brigham logo

Mass General Brigham

Status

Not yet enrolling

Conditions

Sexually Transmitted Infections (Not HIV or Hepatitis)
HIV Infections

Treatments

Behavioral: HIV disclosure intervention

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT05771519
K23MH126771 (U.S. NIH Grant/Contract)
2022P003409

Details and patient eligibility

About

The goal of this clinical trial is to test an HIV disclosure intervention that the investigators are developing focused on men living with HIV in Uganda. The main questions the investigators are trying to answer is whether the HIV disclosure intervention the investigators develop will help men who receive this intervention to disclose their HIV status to a greater extent than men who receive standard care.

Participants assigned to the intervention group will likely participate in the following:

  • Sexual health education
  • Cognitive behavioral therapy strategies
  • Problem-solving skills building
  • Motivational interviewing
  • Developing a personalized HIV disclosure plan
  • Communication skills building
  • Role-playing disclosure strategies

Enrollment

70 estimated patients

Sex

Male

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

For all 3 Aims, "index participants" inclusion criteria will include:

  • men living with HIV
  • with sexually transmitted infection symptoms (e.g., urethral discharge, genital lesions)
  • either not accessing antiretroviral therapy (per self-report109 and/or clinic documentation) or accessing antiretroviral therapy without HIV viral suppression
  • age ≥18 years,
  • with at least one sexual partner in the past three months

Aims 2 and 3 have the additional inclusion criteria:

  • men living with HIV without HIV disclosure to at least one partner.

In Aims 2 and 3, male participants will be encouraged to invite sexual partners for enrollment. These "partner participants" will have the following inclusion criteria:

  • age ≥18 years
  • partnered with an enrolled man who reports HIV disclosure or plans for HIV disclosure with study support
  • referred by the male participant.

Exclusion Criteria:

  • an inability to speak the local language (Runyankole) or English
  • an inability to provide informed consent

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

70 participants in 2 patient groups

HIV disclosure intervention
Experimental group
Description:
Participants assigned to the intervention group will likely participate in the following: * Sexual health education * Cognitive behavioral therapy strategies * Problem-solving skills building * Motivational interviewing * Developing a personalized HIV disclosure plan * Communication skills building * Role-playing disclosure strategies Procedures in both arms will encompass 3-5 individual sessions lasting 30-60 minutes over 2-3 months. There may also be a booster session at approximately the six-month timepoint.
Treatment:
Behavioral: HIV disclosure intervention
Control
No Intervention group
Description:
Participants assigned to the control group will likely participate in educational topics related to healthy living for men living with HIV. Procedures in both arms will encompass 3-5 individual sessions lasting 30-60 minutes over 2-3 months. There may also be a booster session at approximately the six-month timepoint.

Trial contacts and locations

1

Loading...

Central trial contact

Pooja Chitneni, MD; Jessica Haberer, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems